SIT-话题@MedSci

#SIT#

113篇内容 | 1400人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1910542, encodeId=6353191054224, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Obesity：肥胖是一种慢性病！美国学者提议建立肥胖ICD编码, objectType=article, longId=188804, objectId=85f218880419, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85f218880419, replyNumber=0, likeNumber=0, createdTime=2020-06-05, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85f218880419, moduleTitle=Obesity：肥胖是一种慢性病！美国学者提议建立肥胖ICD编码, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85f218880419)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910540, encodeId=825019105408d, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2020年ASCO-SITC：维生素D可降低免疫疗法引起的结肠炎风险, objectType=article, longId=187774, objectId=2be118e774f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be118e774f2, replyNumber=0, likeNumber=44, createdTime=2020-05-15, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be118e774f2, moduleTitle=2020年ASCO-SITC：维生素D可降低免疫疗法引起的结肠炎风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be118e774f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910534, encodeId=5cb41910534d8, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2020年ASCO-SITC：头颈癌患者接受免疫治疗后，甲状腺功能减退的风险增加, objectType=article, longId=187676, objectId=852f18e67611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=852f18e67611, replyNumber=0, likeNumber=39, createdTime=2020-06-19, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=852f18e67611, moduleTitle=2020年ASCO-SITC：头颈癌患者接受免疫治疗后，甲状腺功能减退的风险增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=852f18e67611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910538, encodeId=6055191053821, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2020年ASCO-SITC：针对高危黑色素瘤患者的个体化疫苗取得喜人结果, objectType=article, longId=187728, objectId=50b618e7282f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50b618e7282f, replyNumber=0, likeNumber=0, createdTime=2020-08-23, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50b618e7282f, moduleTitle=2020年ASCO-SITC：针对高危黑色素瘤患者的个体化疫苗取得喜人结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50b618e7282f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910548, encodeId=1055191054808, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, objectType=article, longId=198654, objectId=e12d1986548a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12d1986548a, replyNumber=0, likeNumber=0, createdTime=2021-07-09, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12d1986548a, moduleTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12d1986548a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910527, encodeId=5a23191052eb0, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据, objectType=article, longId=182548, objectId=646d1825487e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=646d1825487e, replyNumber=0, likeNumber=36, createdTime=2020-09-23, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=646d1825487e, moduleTitle=2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=646d1825487e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910530, encodeId=978c191053032, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=ASIT Biotech花粉过敏药物的功效, objectType=article, longId=184295, objectId=a0ae1842958e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0ae1842958e, replyNumber=0, likeNumber=31, createdTime=2020-05-03, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0ae1842958e, moduleTitle=ASIT Biotech花粉过敏药物的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0ae1842958e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910536, encodeId=3aad1910536ff, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2020年ASCO-SITC：抗生素会降低黑色素瘤患者经免疫检查点抑制剂治疗的有效性, objectType=article, longId=187698, objectId=727018e69811, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=727018e69811, replyNumber=0, likeNumber=34, createdTime=2020-07-29, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=727018e69811, moduleTitle=2020年ASCO-SITC：抗生素会降低黑色素瘤患者经免疫检查点抑制剂治疗的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=727018e69811)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910546, encodeId=21091910546e5, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=OCC 2020 | 伊伐布雷定改善心衰患者症状、心功能和生活质量！POSITIVE研究期中分析结果公布, objectType=article, longId=195385, objectId=e0ca19538516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0ca19538516, replyNumber=0, likeNumber=38, createdTime=2020-07-10, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0ca19538516, moduleTitle=OCC 2020 | 伊伐布雷定改善心衰患者症状、心功能和生活质量！POSITIVE研究期中分析结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0ca19538516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910537, encodeId=5b9f191053e8d, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, objectType=article, longId=187720, objectId=ddb118e72078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb118e72078, replyNumber=0, likeNumber=29, createdTime=2020-10-23, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb118e72078, moduleTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb118e72078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910531, encodeId=cf4b191053155, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2019 SITC共识声明：晚期肾细胞癌（RCC）免疫治疗, objectType=article, longId=185318, objectId=3122185318dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3122185318dd, replyNumber=0, likeNumber=20, createdTime=2020-10-27, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3122185318dd, moduleTitle=2019 SITC共识声明：晚期肾细胞癌（RCC）免疫治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3122185318dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910535, encodeId=f64819105359b, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=2020年ASCO-SITC：Ilixadencel治疗肾癌的II期试验的数据更新, objectType=article, longId=187678, objectId=a86418e6787e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a86418e6787e, replyNumber=0, likeNumber=43, createdTime=2020-10-21, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a86418e6787e, moduleTitle=2020年ASCO-SITC：Ilixadencel治疗肾癌的II期试验的数据更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a86418e6787e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910529, encodeId=7bfc19105297c, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=美国SITC发布，头颈部鳞状细胞癌免疫治疗专家共识, objectType=article, longId=182804, objectId=d88f182804ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d88f182804ee, replyNumber=0, likeNumber=34, createdTime=2020-03-14, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d88f182804ee, moduleTitle=美国SITC发布，头颈部鳞状细胞癌免疫治疗专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d88f182804ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910543, encodeId=91d81910543e1, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=OBESITY：新冠疫情或导致儿童肥胖大流行, objectType=article, longId=191667, objectId=233619166e96, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=233619166e96, replyNumber=0, likeNumber=29, createdTime=2020-05-02, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=233619166e96, moduleTitle=OBESITY：新冠疫情或导致儿童肥胖大流行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=233619166e96)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910528, encodeId=d9301910528c2, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Obesity：体重正常但腰粗，更易患痴呆症, objectType=article, longId=182627, objectId=8db718262e7e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8db718262e7e, replyNumber=0, likeNumber=35, createdTime=2020-09-28, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8db718262e7e, moduleTitle=Obesity：体重正常但腰粗，更易患痴呆症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8db718262e7e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910524, encodeId=605619105240e, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验, objectType=article, longId=176830, objectId=36111e683054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36111e683054, replyNumber=0, likeNumber=33, createdTime=2020-06-01, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36111e683054, moduleTitle=不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36111e683054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910532, encodeId=b708191053278, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=tafasitamab一线治疗DLBCL的I期临床研究已正式开展, objectType=article, longId=185457, objectId=3ff918545e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff918545e72, replyNumber=0, likeNumber=36, createdTime=2020-09-10, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff918545e72, moduleTitle=tafasitamab一线治疗DLBCL的I期临床研究已正式开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ff918545e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910520, encodeId=5103191052079, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Intensity的INT230-6获得FDA的快速通道指定，用于治疗复发或转移性三阴性乳腺癌, objectType=article, longId=164505, objectId=a10e164505e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a10e164505e1, replyNumber=0, likeNumber=0, createdTime=2020-03-14, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a10e164505e1, moduleTitle=Intensity的INT230-6获得FDA的快速通道指定，用于治疗复发或转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a10e164505e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910518, encodeId=26bc19105186a, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=BMC Obesity：尿生物标志物可作为肥胖青少年慢性炎症和内皮功能障碍的预测因子, objectType=article, longId=162604, objectId=526016260443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=526016260443, replyNumber=0, likeNumber=26, createdTime=2019-11-07, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=526016260443, moduleTitle=BMC Obesity：尿生物标志物可作为肥胖青少年慢性炎症和内皮功能障碍的预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=526016260443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910526, encodeId=57ba1910526ee, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, objectTitle=Int J Obesity：澳学者称，孩子将来胖不胖，先看妈妈胖不胖和教育程度, objectType=article, longId=182006, objectId=2e9918200632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e9918200632, replyNumber=0, likeNumber=33, createdTime=2020-08-13, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e9918200632, moduleTitle=Int J Obesity：澳学者称，孩子将来胖不胖，先看妈妈胖不胖和教育程度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e9918200632)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SIT

2020-05-29

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Obesity：肥胖是一种慢性病！美国学者提议建立肥胖ICD编码

2020-06-05

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2020年ASCO-SITC：维生素D可降低免疫疗法引起的结肠炎风险

2020-05-15

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2020年ASCO-SITC：头颈癌患者接受免疫治疗后，甲状腺功能减退的风险增加

2020-06-19

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2020年ASCO-SITC：针对高危黑色素瘤患者的个体化疫苗取得喜人结果

2020-08-23

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤

2021-07-09

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据

2020-09-23

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

ASIT Biotech花粉过敏药物的功效

2020-05-03

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2020年ASCO-SITC：抗生素会降低黑色素瘤患者经免疫检查点抑制剂治疗的有效性

2020-07-29

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

OCC 2020 | 伊伐布雷定改善心衰患者症状、心功能和生活质量！POSITIVE研究期中分析结果公布

2020-07-10

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关

2020-10-23

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2019 SITC共识声明：晚期肾细胞癌（RCC）免疫治疗

2020-10-27

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

2020年ASCO-SITC：Ilixadencel治疗肾癌的II期试验的数据更新

2020-10-21

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

美国SITC发布，头颈部鳞状细胞癌免疫治疗专家共识

2020-03-14

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

OBESITY：新冠疫情或导致儿童肥胖大流行

2020-05-02

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Obesity：体重正常但腰粗，更易患痴呆症

2020-09-28

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验

2020-06-01

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

tafasitamab一线治疗DLBCL的I期临床研究已正式开展

2020-09-10

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Intensity的INT230-6获得FDA的快速通道指定，用于治疗复发或转移性三阴性乳腺癌

2020-03-14

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

BMC Obesity：尿生物标志物可作为肥胖青少年慢性炎症和内皮功能障碍的预测因子

2019-11-07

zhanglin3079 (审核中...)

前往app查看评论内容

#SIT#

Int J Obesity：澳学者称，孩子将来胖不胖，先看妈妈胖不胖和教育程度

2020-08-13

科室
- - 订阅+
  - 更多科室
工具
服务